Pathogen-Resistant Antibiotic Indications Questioned By FDA Cmte.
Executive Summary
Members of FDA's Anti-Infective Drugs Advisory Committee questioned the usefulness of approving antibiotics specifically for pathogen-resistant indications at a March 24 meeting held to discuss the safety and efficacy of Pharmacia & Upjohn's oxazolidinone antibiotic Zyvox (linezolid)
You may also be interested in...
Zyvox Phase IV Studies May Support Penicillin-Resistant Indications
Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.
Zyvox Phase IV Studies May Support Penicillin-Resistant Indications
Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.
Zyvox Comparison To Synercid In VRE Infections Recommended By FDA Cmte.
Pharmacia & Upjohn should conduct clinical trials comparing its oxazolidinone antibiotic Zyvox to Aventis' Synercid in the treatment of infections due to vancomycin-resistant enterococci, FDA's Anti-Infective Drugs Advisory Committee said March 24.